Literature DB >> 29914976

Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.

Victor A Chow1,2,3, Mazyar Shadman1,2,3, Ajay K Gopal1,2,3.   

Abstract

Chimeric antigen receptor T cells demonstrate efficacy in B-cell malignancies, leading to US Food and Drug Administration approval of axicabtagene ciloleucel (October 2017) and tisagenlecleucel (May 2018) for large B-cell lymphomas after 2 prior lines of therapy. Durable remissions are seen in 30% to 40% of study-treated patients, but toxicities of cytokine release syndrome and neurotoxicity require administration in specialized centers. This article reviews data of current diffuse large B-cell lymphoma management, focusing on axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel.
© 2018 by The American Society of Hematology.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29914976      PMCID： PMC6107879          DOI： 10.1182/blood-2018-04-839217

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  24 in total

1.  Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study.

Authors:  E Van Den Neste; N Schmitz; N Mounier; D Gill; D Linch; M Trneny; N Milpied; J Radford; N Ketterer; O Shpilberg; U Dührsen; D Ma; J Brière; C Thieblemont; G Salles; C H Moskowitz; B Glass; C Gisselbrecht
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

2.  Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma.

Authors:  Craig S Sauter; Matthew J Matasar; Jessica Meikle; Heiko Schoder; Gary A Ulaner; Jocelyn C Migliacci; Patrick Hilden; Sean M Devlin; Andrew D Zelenetz; Craig H Moskowitz
Journal:  Blood       Date:  2015-03-10       Impact factor: 22.113

3.  Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era.

Authors:  Philippe Armand; Sarah Welch; Haesook T Kim; Ann S LaCasce; Eric D Jacobsen; Matthew S Davids; Caron Jacobson; David C Fisher; Jennifer R Brown; Erin Coughlin; Arnold S Freedman; Yi-Bin Chen
Journal:  Br J Haematol       Date:  2012-12-29       Impact factor: 6.998

4.  Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study.

Authors:  E Van Den Neste; N Schmitz; N Mounier; D Gill; D Linch; M Trneny; R Bouadballah; J Radford; M Bargetzi; V Ribrag; U Dührsen; D Ma; J Briere; C Thieblemont; E Bachy; C H Moskowitz; B Glass; C Gisselbrecht
Journal:  Bone Marrow Transplant       Date:  2016-09-19       Impact factor: 5.483

5.  Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.

Authors:  Juliane Gust; Kevin A Hay; Laïla-Aïcha Hanafi; Daniel Li; David Myerson; Luis F Gonzalez-Cuyar; Cecilia Yeung; W Conrad Liles; Mark Wurfel; Jose A Lopez; Junmei Chen; Dominic Chung; Susanna Harju-Baker; Tahsin Özpolat; Kathleen R Fink; Stanley R Riddell; David G Maloney; Cameron J Turtle
Journal:  Cancer Discov       Date:  2017-10-12       Impact factor: 39.397

Review 6.  Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.

Authors:  Zachary J Roberts; Marc Better; Adrian Bot; Margo R Roberts; Antoni Ribas
Journal:  Leuk Lymphoma       Date:  2017-10-23

7.  Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.

Authors:  Gustaaf W van Imhoff; Andrew McMillan; Matthew J Matasar; John Radford; Kirit M Ardeshna; Kazimierz Kuliczkowski; WonSeog Kim; Xiaonan Hong; Jette Soenderskov Goerloev; Andrew Davies; María Dolores Caballero Barrigón; Michinori Ogura; Sirpa Leppä; Michael Fennessy; Qiming Liao; Bronno van der Holt; Steen Lisby; Anton Hagenbeek
Journal:  J Clin Oncol       Date:  2016-12-28       Impact factor: 44.544

8.  Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.

Authors:  Christian Gisselbrecht; Bertram Glass; Nicolas Mounier; Devinder Singh Gill; David C Linch; Marek Trneny; Andre Bosly; Nicolas Ketterer; Ofer Shpilberg; Hans Hagberg; David Ma; Josette Brière; Craig H Moskowitz; Norbert Schmitz
Journal:  J Clin Oncol       Date:  2010-07-26       Impact factor: 44.544

Review 9.  Chimeric antigen receptor T-cell therapies for lymphoma.

Authors:  Jennifer N Brudno; James N Kochenderfer
Journal:  Nat Rev Clin Oncol       Date:  2017-08-31       Impact factor: 66.675

10.  Current concepts in the diagnosis and management of cytokine release syndrome.

Authors:  Daniel W Lee; Rebecca Gardner; David L Porter; Chrystal U Louis; Nabil Ahmed; Michael Jensen; Stephan A Grupp; Crystal L Mackall
Journal:  Blood       Date:  2014-05-29       Impact factor: 22.113
View more
  35 in total

1.  Chemically Programmable and Switchable CAR-T Therapy.

Authors:  Junpeng Qi; Kohei Tsuji; David Hymel; Terrence R Burke; Michael Hudecek; Christoph Rader; Haiyong Peng
Journal:  Angew Chem Int Ed Engl       Date:  2020-05-18       Impact factor: 15.336

2.  Safety and efficacy of CAR T cells in a patient with lymphoma and a coexisting autoimmune neuropathy.

Authors:  Khushali S Jhaveri; Ilana Schlam; Noa G Holtzman; Monica Peravali; Perry K Richardson; Saurabh Dahiya; Vera Malkovska; Aaron P Rapoport
Journal:  Blood Adv       Date:  2020-12-08

3.  CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison.

Authors:  Peter Dreger; Sascha Dietrich; Maria-Luisa Schubert; Lorenz Selberg; Andrea Bondong; Mandy Wegner; Peter Stadtherr; Christoph Kimmich; Florentina Kosely; Anita Schmitt; Petra Pavel; Nora Liebers; Thomas Luft; Ute Hegenbart; Aleksandar Radujkovic; Anthony Dick Ho; Carsten Müller-Tidow; Michael Schmitt
Journal:  Blood Adv       Date:  2020-12-22

Review 4.  BMP gene delivery for skeletal tissue regeneration.

Authors:  Maxim Bez; Gadi Pelled; Dan Gazit
Journal:  Bone       Date:  2020-05-21       Impact factor: 4.398

Review 5.  Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation?

Authors:  Peter Dreger; Timothy S Fenske; Silvia Montoto; Marcelo C Pasquini; Anna Sureda; Mehdi Hamadani
Journal:  Biol Blood Marrow Transplant       Date:  2020-01-07       Impact factor: 5.742

6.  Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.

Authors:  Victor A Chow; Ajay K Gopal; David G Maloney; Cameron J Turtle; Stephen D Smith; Chaitra S Ujjani; Mazyar Shadman; Ryan D Cassaday; Brian G Till; Yolanda D Tseng; Edus H Warren; Andrei R Shustov; Manoj P Menon; Sandra Bhark; Utkarsh H Acharya; Erin Mullane; Lindsay M Hannan; Jenna M Voutsinas; Ted A Gooley; Ryan C Lynch
Journal:  Am J Hematol       Date:  2019-05-21       Impact factor: 10.047

Review 7.  Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.

Authors:  William R Strohl; Michael Naso
Journal:  Antibodies (Basel)       Date:  2019-07-03

Review 8.  Immunotherapy in endometrial cancer: rationale, practice and perspectives.

Authors:  Wenyu Cao; Xinyue Ma; Jean Victoria Fischer; Chenggong Sun; Beihua Kong; Qing Zhang
Journal:  Biomark Res       Date:  2021-06-16

9.  Rescuing imperfect antigens for immuno-oncology.

Authors:  Selena J Lorrey; Luis Sanchez-Perez; Peter E Fecci
Journal:  Nat Biotechnol       Date:  2019-09       Impact factor: 54.908

10.  TP53-Mutated Circulating Tumor DNA for Disease Monitoring in Lymphoma Patients after CAR T Cell Therapy.

Authors:  Liting Chen; Wei Mu; Jia Gu; Min Xiao; Liang Huang; Miao Zheng; Chunrui Li; Yi Xiao; Jianfeng Zhou; Xiaolu Long
Journal:  Diagnostics (Basel)       Date:  2021-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.